A new therapeutic approach for severe bleeding
To develop a new treatment of severe bleeding to be used as prophylaxis or on demand. This innovative treatment, given systemically, prolongs the half-life of activated clotting factors at the site(s) of injury by neutralizing the main inhibitor of clotting in the blood, antithrombin III (AT). We will deliver 1) a humanized monoclonal antibody inhibiting AT; 2) cell lines producing the antibody; and 3) proof of concept for efficacy of the antibody in an animal model for severe bleeding.
1 553 990.00€
Biochemistry / Biophysics
Monoclonal Antibodies and Hybridomas